MENU

A Closer Look At GlaxoSmithKline plc

Following Motley Fool analyst Nate Weisshaar’s insights on AstraZeneca, he now turns his attention to Big Pharma rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) after the Serious Fraud Office has launched a criminal investigation into its commercial practices…

GlaxoSmithKline is one of five shares in the FTSE 100 that our top analysts have highlighted in our special report "5 Shares To Retire On". To find out the reasons behind their inclusion, and the names of the other four shares, simply click here to have it delivered competely free to your inbox.

The Motley Fool has recommended shares in GlaxoSmithKline.